Welcome to the OMA Blog

For the past decade, Al Robaina, MD, DABOM, has been helping patients as a board-certified internal medicine physician, helping patients with a variety of conditions such as hypertension, diabetes, and lipid disorders. But as he looked deeper at the root causes of many of those diseases, he realized there was one disease that seemed to be linked to them all: obesity.

For Aradhna Saraswat, MD, DABOM, obesity medicine is about more than helping patients reach their health goals; it’s about creating a space where they can be vulnerable, heard and understood.

For more than 40 years, Deborah Juda, RD, LDN, has dedicated her career to helping people better understand nutrition, weight management and obesity care.

For years, Alicia Shelly, MD, DABOM, built meaningful relationships with patients through primary care, helping them navigate life’s challenges and celebrating their successes along the way. Today, as a board-certified internal medicine physician and a Diplomate of the American Board of Obesity Medicine, Dr. Shelly practices obesity medicine full-time, helping patients through comprehensive and compassionate obesity care.

Medicare coverage of GLP-1s for weight loss indications will occur under the Medicare GLP-1 Bridge Model, rather than the BALANCE Model, through December 31, 2027. Eligible Medicare beneficiaries will continue to have access to covered GLP-1 medications nationwide with a fixed $50 copay through the extended Bridge Model. While the Bridge Model was originally scheduled to end December 31, 2026 – to be replaced by BALANCE on January 1, 2027 – CMS extended the Bridge Model to allow for ongoing coverage of GLP-1 medications given the delay of the BALANCE model. The extension of the Bridge Model will enable eligible Part D beneficiaries across the country to access covered GLP-1 medications through December 2027, regardless of their Part D plan sponsors’ participation decisions. CMS’ announced changes to Medicare coverage of GLP-1 medications are not expected to affect Medicaid coverage of the medications under the BALANCE model.

An international steering group conducted a rigorous global consensus process for renaming polycystic ovary syndrome, leading to a consensus regarding the terminology change

Discover the most effective weight loss medications approved by the FDA. Comprehensive guide on safety, dosage, and efficacy for 2025.

The hypothalamus may be small, but its influence on human physiology is profound. As a central regulator of neuroendocrine function, it plays a critical role in maintaining homeostasis—coordinating hunger and satiety, energy expenditure, sleep–wake cycles, thermoregulation, thirst, and fatigue.1-4 When this finely tuned system is disrupted, the downstream clinical consequences can be severe and lifelong.

The most increase in physical activity (PA) was found to be from infancy to 24 months and then tended to plateau. Greater screen time exposure was associated with a slower rate of PA increase between 6 and 24 months of age. Based on these findings, clinicians should consider integrating PA anticipatory guidance into well-child visits beginning in early infancy, with attention to screen time limits and opportunities for active play. In their original article, Longitudinal Change in Physical Activity in Children 6 to 36 Months of Age , Pate and colleagues not only present the developmental pattern for PA in this age group but also highlight factors that may hinder or promote PA development. Interestingly, screen time was associated with higher PA levels at 6 months but with a slower rate of PA growth by 24 months, suggesting that the negative impact of screen exposure on physical activity accumulates over time rather than appearing immediately. Longitudinal Change in Physical Activity in Children 6 to 36 Months of Age.